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Abstract
Background: Approximately 60–80% of patients with advanced head and neck squamous cell carcinoma (HNSCC) die
within five years after diagnosis. Cisplatin-based chemotherapy is the most commonly used palliative treatment for these
patients. To evaluate the prognostic value of X-linked inhibitor of apoptosis (XIAP) level as a potential biomarker in these
patients, we investigated the relationship between XIAP expression and cisplatin response of these patients and their
prognosis.
Methodology/Principal Findings: Sixty patients with advanced HNSCC were recruited in this study. Expression of XIAP was
examined both before and after chemotherapy and was correlated with chemotherapy response, clinicopathology
parameters and clinical outcomes of the patients. We found that XIAP was expressed in 17 (20.83%) of the 60 advanced
HNSCC samples and the expression was significantly associated with cisplatin resistance (P=0.036) and poor clinical
outcome (P=0.025). Cisplatin-based chemotherapy induced XIAP expression in those post-chemotherapy samples
(P=0.011), was further associated with poorer clinical outcome (P=0.029). Multivariate analysis demonstrated that only
alcohol consumption, lymph node metastasis and XIAP level were independently associated with the prognosis of
advanced HNSCC patients. Inhibiting XIAP expression with siRNA in XIAP overexpressed HNSCC cells remarkably increased
their sensitivity to cisplatin treatment to nearly a 3 fold difference.
Conclusions/Significance: Our results demonstrate that XIAP overexpression plays an important role in the disease course
and cisplatin-resistance of advanced HNSCC. XIAP is a valuable predictor of cisplatin-response and prognosis for patients
with advanced head and neck cancer. Down-regulation of XIAP might be a promising adjuvant therapy for those patients of
advanced HNSCC.
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Introduction
Head and neck squamous cell carcinoma (HNSCC) is the fifth
most common cancer worldwide and is the most common
neoplasm in central Asia [1]. Although early-stage HNSCC have
high cure rates, up to 50% of patients present with advanced
disease [2]. Among these advanced stage HNSCC patients, 60–
80% will die within 5 years after diagnosis [3]. Currently, cisplatin-
based chemotherapy is the most commonly used palliative
treatment for these patients. However, in clinic only a limited
number of patients benefit from cisplatin-based chemotherapy;
other patients are resistant to this therapy and some will die due to
treatment-related toxicity [4]. Therefore, it is essential to look for
predictors or potential biomarkers that may help to identify the
patients who may benefit from cisplatin-based chemotherapy.
Inhibitors of apoptosis proteins (IAPs) represent one set of
potent endogenous modulators of apoptosis in mammalian cells,
which consist of eight members: XIAP, cIAP1, cIAP2, survivin,
NIAP, Bruce, ML-IAP and ILP-2 [5]. These proteins mediate
multiple biological functions that include binding to and inhibit-
ing caspases, regulating cell cycle progression, and modulating
receptor-mediated signal transduction [6]. Among them, X-linked
inhibitor of apoptosis (XIAP) is one of the most potent inhibitor of
caspases and apoptosis. XIAP can directly bind to and inhibit both
the initiator and effector caspases and inhibit both mitochondrial-
dependent and -independent apoptotic pathways [7,8,9]. Recent
findings have shown in vitro, XIAP can cause resistance among
tumor cells when exposed to a variety of apoptotic stimuli,
including chemotherapy [10,11]. However, it is not known if
XIAP expression level could be used to predict the cisplatin
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e31601response of advanced HNSCC. Therefore, the aim of our study
was to investigate the expression of XIAP in advanced HNSCC
and its relationship with cisplatin response and prognosis of these
patients.
Results
XIAP expression level is associated with a poor clinical
outcome of advanced HNSCC patients
XIAP was mainly localized in the cytoplasm of tumor cells
(Figure 1), with highly variable positive rate from 1%–85%.
Nucleus staining was occasionally observed in some post-
chemotherapy samples. Patients whose tumors expressed high
levels of XIAP generally had a poorer prognosis than those
patients whose tumors expressed low levels of XIAP in pre-
chemotherapy’s cancer tissue (overall survival P=0.025, Log Rank
test, Figure 2). XIAP expression rate was not correlated with the
TNM stage, pathologic grade, smoking and alcohol history of
these patients with advanced HNSCC (Table 1). In multivariate
analysis, lymph node metastasis, alcohol consumption and XIAP
expression (pre-chemotherapy) were independent risk factors for
patients’ prognosis (Table 2).
XIAP expression level was associated with chemotherapy
response of patients with advanced HNSCC
All of these advanced HNSCC patients had finished one cycle of
chemotherapy. Among them, 34 cases were complete response
(CR) and partial response (PR) to chemotherapy and 26 cases were
progressive disease (PD) and stable disease (SD). The patients
whose tumors expressed high levels of XIAP were significantly
more resistant to cisplatin chemotherapy and generally had poorer
chemotherapy responses (P=0.005, Table 1). XIAP expression
levels were greatly increased in the post-chemotherapy HNSCC
tissues compared with the pre-chemotherapy samples (P=0.011,
Table 3). XIAP levels in post-chemotherapy samples were also
significantly related to the overall survival rates of these patients
(P=0.029) (Figure 2), although in multivariate analysis, it was not
an independent factor related to the patients’ outcomes.
Inhibiting XIAP expression sensitized HNSCC cell lines to
cisplatin treatment
To investigate the casual relationship of XIAP expression
and drug response of patients, we used siRNA to inhibit XIAP
expression in HNSCC cell line CAL27 and WSU-HN13. Three
siRNAs were designed to inhibit the expression of XIAP in CAL27
and WSU-HN13 cells, and among them, siRNA1 treatment group
obtained near70% reduction of XIAP mRNA expression in both
cells (Figure 3). Compared with the negative control group,
cisplatin IC50 value in siRNA1 group decreased from 0.51 mg/ml
to 0.20 mg/ml (P=0.05, Figure 4) in CAL27 and from 4.32 to
1.82 mg/ml in WSU-HN13.
Discussion
Cisplatin-based neoadjuvant chemotherapy, surgery and radi-
ation therapy used to be regarded as standard regime for advanced
HNSCC patients in high risk; however, the therapeutic effects of
neoadjuvant therapy remain inconclusive due to many random-
ized trials failing to show a survival advantage with the use of
neoadjuvant chemotherapy [12,13]. Although indiscriminate
administration of neoadjuvant chemotherapy addresses no benefit
to patients’ outcome (five-year survival rate was 38.33% in our
study), we found those patients who achieved a clinical response
had a more favorable prognosis (p=0.001, log-rank test), which is
consistent to some previous reports [12,13]. From this point of
view, evaluating how to selectively choose patients who would
positively benefit from neoadjuvant chemotherapy was the decisive
factor for successful treatment [4].
In this study, we found a strong relationship between the
expression level of XIAP and the clinical response and prognosis of
patients with advanced HNSCC. Low XIAP expression was closely
correlated with chemotherapy response and favorable prognosis,
whereas high XIAP expression may predict chemotherapy failure
and poor outcome. The results are consistent with previous reports
showing that the down-regulation of XIAP sensitizes cancer cells to
therapeutic drugs in lung cancer, prostate cancer, ovarian cancer
and pancreatic cancer[14,15,16,17,18,19,20]. Importantly, we
Figure 1. Immunohistochemical staining of XIAP in advanced HNSCC (6400). A: Negative control with PBS instead of first antibody; B: Low
expression of XIAP(the percentage of positive rate ,25%); C: High expression of XIAP(the percentage of positive rate .25%).
doi:10.1371/journal.pone.0031601.g001
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expression of XIAP in advanced HNSCC. The higher XIAP level
in post-chemotherapy samples also associated with a poorer
prognosis of patients. Our results show that XIAP expression is a
primary cause of treatment failure and chemotherapy-induced
XIAP expression led to a poor prognosis of those drug-resistant
patients. Pre-selected XIAP negative patients may benefit from
cisplatin-based neoadjuvant treatment. Our in vitro data further
proposed a potential value of inhibiting XIAP expression to
enhance the effectiveness of chemotherapy.
It should be noted that contrary to most studies, we observed a
positive association between alcohol consumption and overall
survival of advanced HNSCC patients in this study. Interesting, a
similar result has been published recently, which proposed the
differences of our data and cultural tradition might be caused by
different drinking habits: the advanced HNSCC patients from
China often drank liquor with very high concentration of alcohol
(usually .50%), whereas Westerners usually consume drinks with
much lower concentration of alcohol. Such high concentrations of
alcohol may stimulate oral mucosa and destroy bacteria balance,
influencing the disease course of advanced HNSCCC [21]. We
cannot exclude the possibilities of limited sample size and/or other
factors that may have contributed to this observation.
This study was a retrospective case-control study and had some
limitations. In the present study, we chose IHC to evaluate XIAP
expression instead of some quantitative methods primary because
of the unavailability of fresh biopsy tissues. Although IHC is a
semi-quantitative method, it is now the most commonly used,
Table 1. The correlations between XIAP expression and patient characteristics.
Characteristics pre-chemotherapy post-chemotherapy
Low High P Low high P
Gender
Male 31 8 0.067 20 19 0.935
Female 12 9 11 10
Age
,60 26 11 0.761 16 21 0.098
$60 17 6 15 8
cTNM stage
III 13 8 0.218 9 12 0.316
IV 30 9 22 17
Pathologic grade
I 22 9 0.311 13 18 0.465
II 19 6 17 8
I I I 22 13
Lymph node status
Positive 25 13 0.184 15 23
Negative 18 4 16 6
Chemoresponse
SD+PD 15 11 0.036 8 18 0.005
PR+CR 28 6 23 11
Smoking history
Smoking 20 7 0.708 14 13 0.979
No smoking 23 10 17 16
Alcohol history
Drinker 18 7 0.961 11 14 0.315
Nondrinker 25 10 20 15
Overall survival
Censored 20 3 0.025 16 7 0.029
Event 23 14 15 22
doi:10.1371/journal.pone.0031601.t001
Figure 2. Overall survival. A: Overall survival rate by XIAP scores. Patients whose tumors expressed high levels of XIAP generally had a poorer
prognosis than those patients whose tumors expressed low levels of XIAP in pre-chemotherapy cancer tissue; B: Overall survival rate by
chemoresponse. Patients whose tumors were responsive to chemotherapy generally had a better prognosis than those patients whose tumor was
resistant to chemotherapy; C: XIAP scores of post-chemotherapy samples. XIAP levels in post-chemotherapy samples were also significantly related to
the patient overall survival rates.
doi:10.1371/journal.pone.0031601.g002
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Also, the rate of high XIAP expression in the pre-chemotherapy
samples was only 20.83%, whereas the chemotherapy response
rate (CR+PR) of the patients was 43.34%. It is more than likely
that many factors may contribute to the overall drug response in
advanced HNSCC; XIAP expression may just be one of many
factors involved.
Findings from the current study have potentially important
clinical implications. First, our study showed, for the first time that
XIAP expression is associated with chemotherapy response and
may be used as a biomarker to predict clinical outcomes of
advanced HNSCC patients, particularly to those who have had
cisplatin-based chemotherapeutic therapy. Second, XIAP expres-
sion may be a useful biomarker to select patients who have the
greatest chance of benefiting from cisplatin-based neoadjuvant
chemotherapy. Finally, the causal relationship between XIAP
expression level and chemotherapy response indicate that down-
regulation of XIAP might be a promising adjuvant therapy for
advanced HNSCC patients.
Materials and Methods
Ethics statement
This study was approved by the Ethics Committee of Ninth
People’s Hospital, Shanghai Jiao Tong University School of
Medicine and carried out according to the recommendations of
the Declaration of Helsinki. No informed consent (written or
verbal) was obtained for use of retrospective tissue samples from
the patients within this study, many of whom were deceased, since
the Ethics Committee, who waived the need for consent, did not
deem this necessary. All samples were anonymous.
Table 3. The expression of XIAP in pre- and post-
chemotherapy samples.
XIAP expression Low (%) High (%)
Pre-chemotherapy 43(72) 17(28)
Post-chemotherapy 31(52) 29(48)
P 0.011
doi:10.1371/journal.pone.0031601.t003
Figure 3. XIAP expression inhibited by siRNA. Inhibition efficacy
of siRNA-1, siRNA-2 and siRNA-3 on the expression of XIAP mRNA was
examined in CAL27 cell (Upper) and WSU-HN13 cell (Lower) with Real-
time PCR. XIAP siRNA1 treatment group obtained near 70% reduction
of XIAP mRNA expression in both cells.
doi:10.1371/journal.pone.0031601.g003
Table 2. Cox proportional hazards regression models in estimating overall survival.
Characteristics Hazard ratio 95% Confidence interval P
Univariate survival analysis
Age 1.254 0.653–2.405 0.497
Clinical stage 0.885 0.455–1.722 0.719
Pathologic grade 1.303 0.669–2.536 0.437
Gender 0.828 0.415–1.653 0.593
Lymph node status 2.772 1.301–5.906 0.008
XIAP expression(pre-chemotherapy) 2.108 1.077–4.123 0.029
XIAP expression(post-chemotherapy) 2.045 1.059–3.950 0.033
Smoking history 0.635 0.333–1.211 0.168
Drinking history 0.442 0.231–0.847 0.014
Multivariate survival analysis
Lymph node status 2.544 1.186–5.457 0.016
Alcohol history 0.398 0.202–0.783 0.008
XIAP expression(pre-chemotherapy) 2.311 1.151–4.643 0.019
doi:10.1371/journal.pone.0031601.t002
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Human HNSCC cell line CAL27, which was resistant to
treatment with cisplatin, was obtained from the American Tissue
Cell Collection (Manassas, VA, USA) and cultured in DMEM
(Gibco, USA) supplemented with 10% fetal bovine serum (FBS),
1% glutamine, and 1% penicillin-streptomycin. WSU-HN13 cell
line[23] was gifted from University of Maryland Dental School
(Baltimore, MD, USA) and also cultured in DMEM (Gibco, USA)
supplemented with 10% fetal bovine serum (FBS), 1% glutamine,
and 1% penicillin-streptomycin.
Patients and Tumor Specimens
Sixty patients with advanced HNSCC (clinical stage III/Iva;
UICC/AJCC. 7 ed., 2010) were recruited in this study. All
patients have accepted cisplatin-based neoadjuvant chemotherapy
followed by radical tumor resection within two to three weeks of
completing chemotherapy at the Department of Oral and
Maxillofacial Surgery, Ninth People’s Hospital, Shanghai Jiao
Tong University from January 1999 to December 2004.
The clinical response of chemotherapy was evaluated no less
than 2 weeks after patients completed chemotherapy according to
response evaluation criteria in solid tumors (RECIST) [24]. A CR
was defined as the complete disappearance of all measurable
lesions, without the appearance of any new lesions. A PR was
defined as a reduction in bi-dimensionally measurable lesions by at
least 50 percent of the sum of the products of their largest
perpendicular diameters and an absence of progression in other
lesions, without the appearance of any new lesions. SD [9] was
defined as a reduction in tumor volume of less than 50 percent or
an increase in the volume of one or more measurable lesions of less
than 25 percent, without the appearance of any new lesions. PD
was defined as an increase in the size of at least one bi-
dimensionally measurable lesion by at least 25 percent and the
appearance of new lesions. Patients’ clinicopathologic information
is presented in Table 4. All patients were treated with standard
curative operations with negative resection margin. All patients
received post-operative radiotherapy within two-six weeks of
completing surgery. Total dose for primary tumor area and neck
of positive nodes was 6000cGy and for primary tumor and neck of
negative nodes was 5000 cGy.
Western Blot Analysis
Total protein was lysed in 26 lysis buffer containing 125 mM
Tris-HCl (pH 6.8), 5% w/v SDS, and 24.75% glycerol. 40 mg
proteins were separated using 12%SDS-PAGEand then transferred
to PVDF membranes. After overnight incubation with monoclonal
mouse-anti-human XIAP (BD, USA) in a dilution of 1:4000 and one
hour incubation with IRDye 800CW goat anti-mouse secondary
antibody (LI-COR, USA), the signal was scanned and analyzed
using the Odyssey Infrared Imaging System (LI-COR Biosciences,
USA). b-actin (Sigma-Aldrich, USA) was used as an internal control.
Real-time PCR
The total RNA was isolated using TRIzol reagent (Invitrogen,
USA). 1 mg total RNA wasreverse transcribed into cDNA using
oligo-dT primer and PrimeScript II RTase (TaKaRa, Japan)
according to the manufacturer’s instructions. Real-time PCR was
performed with Thermal Cycler Dice Real Time System
(TaKaRa, Japan). Primers for PCR were designed with Primer
ExpressH software v3.0 (Applied Biosystem, USA). The primer
sequences of XIAP were: 59-CCGGCTGTCCTGGCGCGAAA-
39 and 59-GCTCGTGCCAGTGTTGATGCTGA-39. The prim-
er sequences of b-actin were: 59-CCTGGCACCCAGCACAAT-
39 and 59-GGGCCGGACTCGTCATACT-39, and the primer
sequences of GAPDH were: 59- AATTGAGCCCGCAGCC-
TCCC -39 and 59-ACCAGGCGCCCAATACGACC-39. All the
Figure 4. Inhibiting XIAP expression sensitized both CAL27and WSU-HN13 to cisplatin treatment. XIAP siRNA-1 effectively inhibited the
expression of XIAP protein in both CAL27 and WSU-HN13 cells (Upper) and decreased the cisplatin IC50 value from 0.51 mg/ml to 0.20 mg/ml in
CAL27 and from 4.32 to 1.82 mg/ml in WSU-HN13 (Lower).
doi:10.1371/journal.pone.0031601.g004
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genomic DNA. Dissociation curve analysis was included in all
reactions to exclude non-specific amplification. The relative
quantity of XIAP mRNA level was calculated based on the
standard DDCT methods [25]. Both b-actin and GAPDH were
used as internal control.
siRNA Knockdown
Three anti-XIAP siRNAs each targeting the two splice variants
of XIAP and one FAM-labeled negative control siRNA (non-
target sequence), were synthesized by GenePharma (Shanghai,
China). The sequences were: siRNA1: GGUCAGUACAAA-
GUUGAAATT, siRNA2: GCAGGUUGUAGAUAUAUCATT,
siRNA3: CCGGAAUCUUAAUAUUCGATT and negative con-
trol: AAUUCUCCGAACGUGUCACGU. Transfection was
performed using Lipofectamine 2000 (Invitrogen, USA) following
manufacturer’s protocol.
Immunohistochemistry
Pre- and post-chemotherapy representative tissue paraffin
blocks were cut into 5 mm sections for standard immunohisto-
chemical staining (IHC). After heat-induced antigen retrieval in
citric acid buffer (pH7.0) for 20 min and blocking in 5% Goat
serum for 30 min , slides were incubated with monoclonal mouse
anti-human XIAP (BD, USA) at a dilution of 1:100 at 4uC
overnight. The omission of the primary antibody served as
negative control. Bound antibody was detected by a Super
Sensitive IHC Detection System (BioGenex, USA), according to
the manufacturer’s protocol. The sections were visualized with
diaminobenzidine tetrahydrochloride (Sigma, USA) solution and
counterstained with Harris hematoxylin. The staining result was
determined by counting 1000 tumor cells in three 1006
magnification fields by two independent pathologists and further
classified as low expression (the percentage of positive rate ,25%)
and high expression (the percentage of positive rate $25%).
Drug Sensitivity Assay
Cells were plated in 96-well plates at a density of 4610
3 cells/well
and further incubated for 24 h. 6 h after transfection with negative
control or siRNA, the medium was removed and replaced with fresh
medium containingone of serial dilutions of DDP for another 72 h,
including a negative control without DDP. Then, 20 ml sterile MTT
dye (3-[4,5-dimethylthiazol-2-yl]-2,5-di-phenyltetrazolium bromide,
5 mg dissolved in 1 ml phosphate-buffered saline; Sigma, USA) was
added to the culture medium to a final concentration of 0.5 mg/ml
and incubated at 37uC for 4 h. Subsequently, the formazan crystals
were solubilized with 150 ml of dimethylsulfoxide for 10 min.
Spectrometric absorbance at 490 nm was measured with a
microplate reader. Each experiment was performed in triplicate.
Statistical Analysis
The SPSS 17.0 software package was used for statistical
analysis. Frequencies were compared with Fisher’s exact test, 62
contingency test, or non-parametric tests as appropriate. We
estimated survival and time-to-progression curves using the
Kaplan-Meier method and compared them using a two-sided
log-rank test. Multiple logistic regressions that used a Cox
proportional hazards model were used to determine whether the
molecular characteristics of the tumors independently predicted
survival in our cohort of advanced HNSCC patients. P,0.05 were
considered statistically significant.
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